14 Sep 2017 12:46
Abzena plc
Result of Annual General Meeting
Cambridge, UK, 14 September 2017: Abzena plc (AIM: ABZA, 'Abzena' or the 'Group'), the life sciences group providing services and technologies to enable better biopharmaceutical products, announces that at its Annual General Meeting held today at 10am on the Babraham Research Campus in Cambridge, all resolutions were duly passed on a show of hands.
Details of the votes received in relation to each of the resolutions (which are more particularly described in the Notice of Annual General Meeting dated 28 July 2017) are as follows:
Resol
| Vote For | % In favour | Votes Against | % Against | Votes Abstain | % Abstain | Total Votes |
1 | 153,588,233 | 100 | 0 | 0 | 0 | 0 | 153,588,233 |
2 | 153,588,233 | 100 | 0 | 0 | 0 | 0 | 153,588,233 |
3 | 153,588,233 | 100 | 0 | 0 | 0 | 0 | 153,588,233 |
4 | 153,588,233 | 100 | 0 | 0 | 0 | 0 | 153,588,233 |
5 | 153,588,233 | 100 | 0 | 0 | 0 | 0 | 153,588,233 |
6 | 153,588,233 | 100 | 0 | 0 | 0 | 0 | 153,588,233 |
7 | 153,588,233 | 100 | 0 | 0 | 0 | 0 | 153,588,233 |
8 | 153,588,233 | 100 | 0 | 0 | 0 | 0 | 153,588,233 |
Percentage figures have been subject to rounding as considered appropriate.
The total number of ordinary shares of £0.002 each eligible to be voted at the Annual General Meeting was 213,639,236.
Enquiries:
Abzena plc John Burt, Chief Executive Officer Julian Smith, Chief Financial Officer
| +44 1223 903498 |
Numis (Nominated Adviser and Broker) Clare Terlouw / James Black / Paul Gillam
| +44 20 7260 1000 |
|
|
N+1 Singer (Joint Broker) Aubrey Powell / Liz Yong
| +44 20 7496 3000 |
Instinctif Partners Melanie Toyne Sewell / Alex Shaw | +44 20 7457 2020 abzena@instinctif.com |
Notes to Editors
About Abzena
Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.
The term 'ABZENA Inside' is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on 'ABZENA Inside' products.
Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):
· Immunology research studies, including immunogenicity assessment of candidate biopharmaceutical products;
· Protein engineering to create humanized antibodies and deimmunised therapeutic proteins;
· Cell line development for the manufacture of recombinant proteins and antibodies;
· Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies;
· Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs);
· Proprietary site-specific conjugation technologies and novel payloads for ADC development; and
· GMP manufacturer of ADC linkers, payloads & combined linker-payloads.
For more information, please see www.abzena.com